Netaf Pregnancy

• Pregnancy of Netaf in details
• Netaf breastfeeding
• Netaf reviews

Pregnancy of Netaf in details

Netaf ophthalmic has been assigned to pregnancy category C by the FDA. Some animal studies have revealed evidence of teratogenicity with doses up to 312 times higher than the normal human dose. There are no controlled data in human pregnancy. Very small amounts of Netaf were detected in umbilical vein samples after its intramuscular administration during labor and delivery. Netaf ophthalmic is only recommended for use during pregnancy when benefit outweighs risk.

Netaf is known to cross the placenta. In one study, 32 women received Netaf 10 mg one time by intramuscular injection to relieve pain during labor. Netaf levels were obtained from maternal plasma and from the umbilical cord at the time of delivery, with sample times ranging from 0.5 to 6.5 hours post-dose. Netaf concentrations ranged from 0.02 to 0.12 mcg/mL in cord blood and from 0.2 to 0.9 mcg/mL in maternal plasma. The mean cord blood to maternal plasma concentration ratio was 0.12. In another study, 18 women were randomly assigned to receive Netaf 10 mg or meperidine 50 mg or 100 mg one time by intramuscular injection to relieve pain during labor. An analysis of platelet aggregation in whole blood obtained from the neonates revealed a significant inhibition of arachidonic acid and collagen-induced platelet aggregation in those infants whose mothers received Netaf. ADP-induced aggregation was not affected. The clinical significance of this finding remains to be determined. Data on the use of Netaf during pregnancy, other than for the management of labor pain, are lacking.

Netaf breastfeeding

A peri/postnatal study in rats showed reduction in postnatal growth and survival of the offspring when Netaf was administered to lactating rats at oral dose levels greater than 4.8 mg/kg/day. In human breast milk, limited data suggests milk levels of Netaf are low with usual oral doses, however, milk levels have not been measured after higher injectable doses. Available evidence has not shown any specific adverse events in nursing infants.

Use is contraindicated Excreted into human milk: Yes

See references

References for pregnancy information

1. "Product Information. Sprix (Netaf)." American Regent Laboratories Inc, Shirley, NY.
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. Cerner Multum, Inc. "Australian Product Information." O 0
4. "Product Information. Netaf Tromethamine (Netaf)." Hospira Inc, Lake Forest, IL.
5. "Product Information. Toradol (Netaf)." Roche Laboratories, Nutley, NJ.

References for breastfeeding information

1. "Product Information. Toradol (Netaf)." Roche Laboratories, Nutley, NJ.
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. "Product Information. Sprix (Netaf)." American Regent Laboratories Inc, Shirley, NY.
4. "Product Information. Netaf Tromethamine (Netaf)." Hospira Inc, Lake Forest, IL.
5. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
6. Cerner Multum, Inc. "Australian Product Information." O 0

References

1. PubMed Health. "Ketorolac (Into the eye): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
2. PubMed Health. "Domperidone (Oral route): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
3. Human Metabolome Database (HMDB). "Domperidone: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).

Reviews

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology